New antibody drug ZMA001 enters first human safety trial

NCT ID NCT05967299

Recruiting now Disease control Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1 trial tests the safety of a new drug called ZMA001 in 96 healthy adults. ZMA001 is a monoclonal antibody designed to reduce lung damage in pulmonary arterial hypertension (PAH), a serious condition. Participants receive a single dose of the drug or placebo and are monitored for about 16 weeks. This is the first time ZMA001 is given to humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZMA001 (a monoclonal antibody)
What this could lead to: If successful, this could lead to a new treatment for pulmonary arterial hypertension (PAH), a serious lung disease.
What could go wrong: This is a very early phase 1 trial in healthy people, not patients. It only tests safety and dosing, not whether the drug works for PAH. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION (PAH)

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.